Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25848841 | 0.89 | EPHX2 (0.42) | EPHX2NR1H4HDAC3HDAC1HDAC6 | |
| SCHEMBL25848955 | 0.89 | EPHX2 (0.46) | EPHX2NR1H4HDAC3HDAC1HDAC6 | |
| SCHEMBL25848823 | 0.87 | EPHX2 (0.61) | EPHX2NR1H4HDAC3HDAC6CA1 | |
| SCHEMBL25848940 | 0.83 | LSS (0.50) | EPHX2NR1H4HDAC3HDAC1HDAC6 | |
| SCHEMBL25848839 | 0.80 | ALDH1A1 (0.49) | HDAC3HDAC1HDAC6HDAC4MEN1 | |
| SCHEMBL25848951 | 0.78 | EPHX2 (0.42) | EPHX2NR1H4HDAC3HDAC1HDAC6 | |
| SCHEMBL25848811 | 0.77 | SMN1; SMN2 (0.51) | EPHX2NR1H4HDAC3HDAC1HDAC6 | |
| SCHEMBL24196149 | 0.76 | HDAC3 (0.44) | EPHX2NR1H4HDAC3HDAC1HDAC6 | |
| SCHEMBL24196383 | 0.75 | EPHX2 (0.42) | EPHX2NR1H4HDAC3HDAC1HDAC6 | |
| SCHEMBL25848828 | 0.75 | EPHX2 (0.53) | EPHX2NR1H4HDAC3HDAC6CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219921-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | EPHX2 2590/4885NR1H4 3085/4885HDAC3 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.